torcetrapib has been researched along with drf 2725 in 1 studies
| Studies (torcetrapib) | Trials (torcetrapib) | Recent Studies (post-2010) (torcetrapib) | Studies (drf 2725) | Trials (drf 2725) | Recent Studies (post-2010) (drf 2725) |
|---|---|---|---|---|---|
| 273 | 28 | 83 | 41 | 3 | 4 |
| Protein | Taxonomy | torcetrapib (IC50) | drf 2725 (IC50) |
|---|---|---|---|
| Chain A, peroxisome proliferator activated receptor gamma | Homo sapiens (human) | 0.092 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.092 | |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | 0.98 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, CB; Li, S | 1 |
1 review(s) available for torcetrapib and drf 2725
| Article | Year |
|---|---|
[Advances in the study of anti-atherosclerosis drugs].
Topics: Apolipoprotein A-I; Atherosclerosis; Benzoates; Benzylamines; Cholesterol Ester Transfer Proteins; DNA-Binding Proteins; Humans; Liver X Receptors; Molecular Structure; Orphan Nuclear Receptors; Oxazines; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Quinolines; Receptors, Cytoplasmic and Nuclear | 2007 |